Guidance from outcome trials: What are the clinical implications?
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.
Video navigation menu
- HF is common in diabetes and the other way around. What can trial results teach us about treating these patients? 0:32
- novel classes of glucose-lowering agents have varying effects on the risk of HF, but members within a class also vary 3:49
- Improvement of HF outcomes achieved with a glucose-lowering drug 5:50
- Speculation on the mechanisms responsible for the CV benefit observed with empagliflozin therapy 8:45
- Comparing findings with different novel drugs to fine-tune therapeutic strategies 10:09
- Ongoing CV outcomes trials with novel diabetes drugs 12:44
This lecture by prof Faiez Zannad was part of a CME accredited symposium: Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?' held at ESC Heart Failure 2018 in Vienna, Austria.
Faiez Zannad is Professor of Therapeutics and Cardiology. He is at the Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU) of Nancy since 1995.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim.